RxDoctor Payments Data

Pervez Ahmed, MD

Cardiovascular Disease · Bethpage, NYNPI 1548359110

Payments from drug & device makers

$5,325in general payments, 2019–2025

Across 22 payments — averaging $242.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4K
  • Boston Scientific$1K
  • Medtronic$262
  • Atricure, Inc.$123
  • E.r. Squibb & Sons, L.L.C.$117
  • Chiesi USA, Inc.$24
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$3,60068%
  • Food & beverage$1,72532%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer3$3,774
Boston Scientific13$1,010
Medtronic(2 entities)2$262
Atricure, Inc.1$123
E.r. Squibb & Sons, L.L.C.1$117
Chiesi USA, Inc.1$24
Novartis1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,325 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$36,303
Medicare patients
124
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$126,627
EntrestoSacubitril/Valsartan20$30,750
Metoprolol Succinate199$3,380
Rosuvastatin Calcium108$1,871
Atorvastatin Calcium91$1,107
Losartan Potassium66$992
Bumetanide43$869
Ezetimibe23$774
Amlodipine Besylate81$614
Midodrine Hcl11$514
ClopidogrelClopidogrel Bisulfate36$511
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$435
Hydralazine Hcl20$372
Carvedilol30$363
Furosemide75$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$3,774$126,627106 claims
NovartisEntresto$13$30,75020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Bethpage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →